A Phase 3 interventional study of JNJ-77242113 in Generalized Pustular Psoriasis and Erythrodermic Psoriasis, sponsored by Janssen Pharmaceutical K.K.. Active, not recruiting at 12 sites in Japan. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Psoriasis by Johnson & Johnson — 3 open to participants now, 12 under way, 7 of them phase 3. Psoriasis · Johnson & Johnson.
Among the 76 studies in Psoriasis by Johnson & Johnson, this one is the 54th largest by enrollment of the 58 interventional ones that give a count, is one of 3 that started in 2024, is one of 36 in phase 3, reaches primary completion later than 5 of the 11 other live ones, and was the 71st registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →3 of the 76 studies in Psoriasis by Johnson & Johnson are open now, in 3 countries. Recruiting first, the newest first:
Janssen-Cilag Kft. · Sites in Hungary
Ages 18+
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
Janssen Research & Development, LLC · Sites in Romania
Ages 18+
By country, each count listing its studies:
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 13 · Phase 3 36 · Phase 4 4
First in 2002; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 222 across the 58 interventional studies, 363 across the 18 observational. Of the 64 that completed or were terminated, 33 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Pharmaceutical K.K., one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Pharmaceutical K.K. is the lead sponsor of 126 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 7 (50%) have results posted.
1 of the studies in Psoriasis by Johnson & Johnson that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07654751Janssen Research & Development, LLCA Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically | 2027-08-31 |
Add it to your calendar (.ics) → With an account.
Among the 76 studies in Psoriasis by Johnson & Johnson, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate how effective JNJ-77242113 is in participants with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with GPP or EP will receive JNJ-77242113 tablet orally.
Drug: JNJ-77242113
JNJ-77242113 tablet will be administered orally.
Percentage of Participants With Generalized Pustular Psoriasis (GPP) Who Experienced Treatment Success at Week 16
Percentage of participants with GPP who experienced treatment success at Week 16 was reported. Treatment success for GPP was defined as at least "minimally improved" rating in Clinical Global Impression (CGI) scale for GPP based on Japanese Dermatological Association (JDA) total score. JDA severity index includes skin symptoms (area of erythema with pustules, total area of erythema, and area of edema; each scored 0-3) and systemic/laboratory findings (fever, white blood cell count, C-reactive protein, and serum albumin; each scored 0-2). JDA total score was sum of 2 assessments ranging from 0 (best) to 17 (worst). CGI ratings were defined as: 1=Very much improved (greater than or equal to \[\>=\]3-point reduction in JDA total score), 2=Much improved (1-2-point reduction), 3=Minimally improved (no change in JDA total score, but \>=20 percent (%) reduction in area of erythema with pustules or meaningful improvement in \>=1 other parameter), 4=No change, 5=Worsened. Higher score = worsening.
Time frame: Week 16
Percentage of Participants With Erythrodermic Psoriasis (EP) Who Experience Treatment Success at Week 16
Percentage of participants with EP who experienced treatment success at Week 16 was reported. Treatment success for EP was defined as at least "minimally improved" rating in CGI scale for EP. The CGI scale is a clinician-rated 5-point scale with the following categories: 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Worsened. Higher score indicated worsening.
Time frame: Week 16
Percentage of Participants With GPP Who Experienced Treatment Success Over Time Based on CGI Scale According to JDA Total Score
Time frame: From baseline (Week 0) to Week 156
Percentage of Participants With EP Who Experienced Treatment Success Over Time Based on CGI Scale
Time frame: From Baseline (Week 0) to Week 156
Change From Baseline in the Total Score of the Japanese Dermatological Association (JDA) Severity Index for GPP Over Time
Time frame: From baseline (Week 0) up to Week 156
Change From Baseline in Severity Classification of JDA Severity Index for GPP Over Time
Time frame: From baseline (Week 0) up to Week 156
Change From Baseline in the Body Surface Area (BSA) of Involvement of Lesion for EP Over Time
Time frame: From baseline (Week 0) up to Week 156
Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) Over Time
Time frame: Baseline (Week 0) up to Week 156
Percentage of Participants Who Achieved an IGA Score of Cleared (0) Over Time
Time frame: Baseline (Week 0) up to Week 156
Percent Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Over Time
Time frame: From baseline (Week 0) up to Week 156
Change From Baseline in Dermatology Life Quality Index (DLQI) Score Over Time
Time frame: From baseline (Week 0) up to Week 156
Percentage of Participants Who Achieved DLQI Score of 0 or 1 Over Time
Time frame: Baseline (Week 0) up to Week 156
Change From Baseline in EuroQol-5 Dimension 5-Level (EQ-5D-5L) Over Time: Domain Scores
Time frame: From baseline (week 0) up to Week 156
Change From Baseline in EQ-5D-5L Over Time: Visual Analog Scale (VAS) Scores
Time frame: From baseline (Week 0) up to Week 156
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
Time frame: Baseline (Week 0) up to 160 weeks
| Milestone | GPP: JNJ-77242113 200 mg QD | EP: JNJ-77242113 200 mg QD |
|---|---|---|
| Started | 9 | 10 |
| Completed | 1 | 1 |
| Not completed | 8 | 9 |
| Withdrew: Ongoing | 8 | 9 |
Percentage of participants with GPP who experienced treatment success at Week 16 was reported. Treatment success for GPP was defined as at least "minimally improved" rating in Clinical Global Impression (CGI) scale for GPP based on Japanese Dermatological Association (JDA) total score. JDA severity index includes skin symptoms (area of erythema with pustules, total area of erythema, and area of edema; each scored 0-3) and systemic/laboratory findings (fever, white blood cell count, C-reactive protein, and serum albumin; each scored 0-2). JDA total score was sum of 2 assessments ranging from 0 (best) to 17 (worst). CGI ratings were defined as: 1=Very much improved (greater than or equal to \[\>=\]3-point reduction in JDA total score), 2=Much improved (1-2-point reduction), 3=Minimally improved (no change in JDA total score, but \>=20 percent (%) reduction in area of erythema with pustules or meaningful improvement in \>=1 other parameter), 4=No change, 5=Worsened. Higher score = worsening.
| Percentage of participants | GPP: JNJ-77242113 200 mg QD |
|---|---|
| Percentage of Participants With Generalized Pustular Psoriasis (GPP) Who Experienced Treatment Success at Week 16 | 88.9 (51.8 to 99.7) |
Percentage of participants with EP who experienced treatment success at Week 16 was reported. Treatment success for EP was defined as at least "minimally improved" rating in CGI scale for EP. The CGI scale is a clinician-rated 5-point scale with the following categories: 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Worsened. Higher score indicated worsening.
| Percentage of participants | EP: JNJ-77242113 200 mg QD |
|---|---|
| Percentage of Participants With Erythrodermic Psoriasis (EP) Who Experience Treatment Success at Week 16 | 100.0 (69.2 to 100.0) |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over From Week 0 up to Week 24. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GPP: JNJ-77242113 200 mg QD | 0/9 (0%) | 2/9 (22.2%) | 6/9 (66.7%) |
| EP: JNJ-77242113 200 mg QD | 0/10 (0%) | 1/10 (10%) | 8/10 (80%) |
| Event | GPP: JNJ-77242113 200 mg QD | EP: JNJ-77242113 200 mg QD |
|---|---|---|
| Acquired HaemophiliaBlood and lymphatic system disorders | 1/9 | 0/10 |
| CataractEye disorders | 1/9 | 0/10 |
| PruritusSkin and subcutaneous tissue disorders | 0/9 | 1/10 |
| Event | GPP: JNJ-77242113 200 mg QD | EP: JNJ-77242113 200 mg QD |
|---|---|---|
| NasopharyngitisInfections and infestations | 1/9 | 2/10 |
| KeratitisEye disorders | 1/9 | 0/10 |
| Angular CheilitisGastrointestinal disorders | 1/9 | 0/10 |
| ConstipationGastrointestinal disorders | 1/9 | 0/10 |
| Hepatic Function AbnormalHepatobiliary disorders | 1/9 | 0/10 |
| CystitisInfections and infestations | 1/9 | 0/10 |
| InfluenzaInfections and infestations | 1/9 | 1/10 |
| Oral CandidiasisInfections and infestations | 1/9 | 0/10 |
| Suspected Covid-19Infections and infestations | 1/9 | 0/10 |
| Upper Respiratory Tract InfectionInfections and infestations | 1/9 | 0/10 |
| Age, Continuous(Years) | GPP: JNJ-77242113 200 mg QD | EP: JNJ-77242113 200 mg QD | Total |
|---|---|---|---|
| Mean | 60 ± 11.91 | 56.8 ± 14.01 | 58.3 ± 12.8 |
| Sex: Female, Male(Participants) | GPP: JNJ-77242113 200 mg QD | EP: JNJ-77242113 200 mg QD | Total |
|---|---|---|---|
| Female | 5 | 1 | 6 |
| Male | 4 | 9 | 13 |
| Ethnicity (NIH/OMB)(Participants) | GPP: JNJ-77242113 200 mg QD | EP: JNJ-77242113 200 mg QD | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 9 | 10 | 19 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | GPP: JNJ-77242113 200 mg QD | EP: JNJ-77242113 200 mg QD | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 9 | 10 | 19 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | GPP: JNJ-77242113 200 mg QD | EP: JNJ-77242113 200 mg QD | Total |
|---|---|---|---|
| Japan | 9 | 10 | 19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Feb 2024 to primary completion in Jan 2025, 11 months.
Results were first posted in Jan 2026, 1 year after primary completion.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 11 months is below that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Icotrokinra